AI assistant
Athira Pharma, Inc. — Director's Dealing 2025
Mar 4, 2025
35038_dirs_2025-03-04_17965a98-3a76-4d12-a2df-f850e287571c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2025-03-03
Reporting Person: CHURCH KEVIN (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-03 | Stock Option (Right to Buy) | $0.3762 | A | 87845 | Acquired | 2035-03-02 | Common Stock (87845) | Direct |
| 2025-03-03 | Restricted Stock Units | $ | A | 58563 | Acquired | Common Stock (58563) | Direct |
Footnotes
F1: The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F3: 100% of the RSUs shall vest on the one (1) year anniversary of the grant date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the vesting date.